Last reviewed · How we verify

Frova (FROVATRIPTAN)

Endo Operations · FDA-approved approved Small molecule Quality 62/100

Frova works by binding to serotonin receptors in the brain to relieve migraine symptoms.

Frova (FROVATRIPTAN) is a serotonin-1b and serotonin-1d receptor agonist, a small molecule developed by Endo Pharms and currently owned by Endo Operations. It targets the 5-hydroxytryptamine receptor 1D to treat migraines, which were FDA-approved in 2001. Frova is off-patent, with multiple generic manufacturers available. Key safety considerations include its 24-hour half-life and 27% bioavailability. As an off-patent medication, its commercial status has shifted to generic availability.

At a glance

Generic nameFROVATRIPTAN
SponsorEndo Operations
Drug classSerotonin-1b and Serotonin-1d Receptor Agonist
Target5-hydroxytryptamine receptor 1D
ModalitySmall molecule
Therapeutic areaNeuroscience
PhaseFDA-approved
First approval2001

Mechanism of action

Frovatriptan binds with high affinity to 5-HT1B/1D receptors. The therapeutic activity of frovatriptan succinate tablets is thought to be due to the agonist effects at the 5-HT1B/1D receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.

Approved indications

Common side effects

Drug interactions

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: